The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessment of second-line VEGF-inhibitor therapy in radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC).
 
Lara Dunn
No Relationships to Disclose
 
Alan Loh Ho
Consulting or Advisory Role - AstraZeneca; Eisai; Novartis
Research Funding - AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
 
Sofia Haque
No Relationships to Disclose
 
Matthew G. Fury
Employment - Regeneron (I)
Stock and Other Ownership Interests - Regeneron (I)
Consulting or Advisory Role - Boehringer Ingelheim; Celgene; Egenix; Novartis
Research Funding - AstraZeneca/MedImmune; Novartis; Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron (I)
 
Shrujal S. Baxi
Consulting or Advisory Role - Bayer/Onyx
 
Grace Cullen
No Relationships to Disclose
 
David G. Pfister
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - AstraZeneca; Boehringer Ingelheim; Exelixis; Genentech; Novartis
 
Eric Jeffrey Sherman
Consulting or Advisory Role - Bayer/Onyx; Eisai
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche/Genentech (Inst)